As a stroke prevention device for patients with atrial fibrillation, the Amplatzer Amulet left atrial appendage (LAA) occluder is part of the industry-leading Amplatzer line of structural intervention occluders. The Amulet LAA Occluder is a part of Abbott’s broad structural heart portfolio.
Percutaneous, catheter-based occlusion of the LAA—the therapy provided by the Amplatzer Amulet LAA Occluder—is an increasingly performed procedure aiming to reduce the risk of stroke in patients with nonvalvular atrial fibrillation.1 Current evidence suggests that transcatheter occlusion of the LAA reduces the risk of thromboembolic complications associated with nonvalvular atrial fibrillation.2
Reducing Stroke RiskDavid Hildick-Smith, MD, Royal Sussex County Hospital, Brighton, England
“What this therapy [use of the Amplatzer Amulet LAA Occluder] does for the patient is twofold. One, it physically deals with the problem and reduces the risk of stroke very substantially. But more than that, it also offers patients a peace of mind.”
AMPLATZER Amulet LAA Occluder
AP2947041-WBO Rev. A
- Landmesser U, et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study. EuroIntervention. 2017;13:867-876.
- Lewalter T. An update and current expert opinions on percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation. Europace. 2013; 15:652-656.